Norethisterone
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
Norethisterone
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13873E | Primolut N | Tablet 5 mg (oral) | Not stated in the data compiled for this report |
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): hypertension, epilepsy, liver disease, gallbladder disease, kidney disease, diabetes mellitus and hyperglycaemia, hypertriglyceridaemia, porphyria, hypothyroidism, asthma, systemic lupus erythematosus, hypercalcaemia, anxiety and dysthymic disorders, and female breast carcinoma.
- Drug interactions: 100 interactions were found; the 20 returned were all rated Moderate. Most involve glucose-lowering agents: acarbose, metformin, alogliptin, linagliptin, dapagliflozin, nateglinide, exenatide, dulaglutide, lixisenatide, albiglutide, pramlintide, metreleptin, and several insulins (aspart protamine, degludec, detemir, human). Others include aprepitant, clotrimazole and prucalopride.
Please refer to the TGA-approved Product Information (PI) for official warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.